We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
Cap. Flow
+$76.2M
Cap. Flow %
1.6%
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$190M
2
INSM icon
Insmed
INSM
+$168M
3
GILD icon
Gilead Sciences
GILD
+$130M
4
UTHR icon
United Therapeutics
UTHR
+$105M
5
BBIO icon
BridgeBio Pharma
BBIO
+$81.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$121M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.6M
3
RVMD icon
Revolution Medicines
RVMD
+$72.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$63.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Technology 0.03%
3 Communication Services 0.01%
4 Consumer Discretionary 0.01%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
126
Cardinal Health
CAH
$54.5B
$202K ﹤0.01%
852
-11
-1% -$2.29K
COGT icon
127
Cogent Biosciences
COGT
$6.57B
$188K ﹤0.01%
+4,870
New +$170K
TEM
128
Tempus AI
TEM
$9.43B
$186K ﹤0.01%
3,213
-1,737
-35% -$87.1K
COR icon
129
Cencora
COR
$59.5B
$163K ﹤0.01%
576
-1,140
-66% -$329K
PTCT icon
130
PTC Therapeutics
PTCT
$6B
$133K ﹤0.01%
1,626
-309
-16% -$22.3K
CAI
131
Caris Life Sciences
CAI
$6.14B
$114K ﹤0.01%
6,418
– –
RYTM icon
132
Rhythm Pharmaceuticals
RYTM
$7.97B
$113K ﹤0.01%
1,016
– –
ARWR icon
133
Arrowhead Research
ARWR
$12.3B
$97.1K ﹤0.01%
1,191
-354
-23% -$26.1K
NVDA icon
134
NVIDIA
NVDA
$5.45T
$81.6K ﹤0.01%
408
– –
LH icon
135
Labcorp
LH
$25.8B
$78.4K ﹤0.01%
280
– –
BIIB icon
136
Biogen
BIIB
$31B
$73K ﹤0.01%
338
-3,315
-91% -$634K
BMY icon
137
Bristol-Myers Squibb
BMY
$131B
$70.1K ﹤0.01%
1,216
-15,822
-93% -$909K
WAT icon
138
Waters Corp
WAT
$40.5B
$67.1K ﹤0.01%
+179
New +$61.1K
MSFT icon
139
Microsoft
MSFT
$3.68T
$64.2K ﹤0.01%
172
– –
IQV icon
140
IQVIA
IQV
$39B
$56.6K ﹤0.01%
293
-447
-60% -$77.9K
INCY icon
141
Incyte
INCY
$24.4B
$55.1K ﹤0.01%
486
– –
MTD icon
142
Mettler-Toledo International
MTD
$28.4B
$46K ﹤0.01%
36
– –
A icon
143
Agilent Technologies
A
$42B
$43.8K ﹤0.01%
330
-334
-50% -$40.7K
QCOM icon
144
Qualcomm
QCOM
$174B
$36.4K ﹤0.01%
197
– –
ZTS icon
145
Zoetis
ZTS
$30.4B
$28K ﹤0.01%
390
-143
-27% -$13.5K
ORCL icon
146
Oracle
ORCL
$434B
$28K ﹤0.01%
191
– –
DGX icon
147
Quest Diagnostics
DGX
$25.9B
$27.8K ﹤0.01%
131
– –
RXRX icon
148
Recursion Pharmaceuticals
RXRX
$1.71B
$17K ﹤0.01%
4,627
– –
ACN icon
149
Accenture
ACN
$108B
– –
-1,500
Closed -$297K
ADBE icon
150
Adobe
ADBE
$105B
– –
-1,200
Closed -$292K
3 4 5
6
7

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Bellevue Group's Q2 2026 Portfolio in Review

As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

  • Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
  • Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
  • Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
  • Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
  • Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.